ME02540B - Modulatori optoidnih receptora - Google Patents
Modulatori optoidnih receptoraInfo
- Publication number
- ME02540B ME02540B MEP-2016-232A MEP23216A ME02540B ME 02540 B ME02540 B ME 02540B ME P23216 A MEP23216 A ME P23216A ME 02540 B ME02540 B ME 02540B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical formulation
- pharmaceutical
- sodium
- pharmaceutically acceptable
- formulation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 229930006000 Sucrose Natural products 0.000 claims 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 239000005720 sucrose Substances 0.000 claims 6
- 229920002261 Corn starch Polymers 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008120 corn starch Substances 0.000 claims 4
- -1 disintegrator Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229960004903 invert sugar Drugs 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 241000416162 Astragalus gummifer Species 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 229920001615 Tragacanth Polymers 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims 2
- 230000000181 anti-adherent effect Effects 0.000 claims 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 229960005069 calcium Drugs 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 2
- 229960002023 chloroprocaine Drugs 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 2
- 229960001231 choline Drugs 0.000 claims 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 2
- 229940043237 diethanolamine Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000013583 drug formulation Substances 0.000 claims 2
- 229940012017 ethylenediamine Drugs 0.000 claims 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229960003194 meglumine Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 235000019371 penicillin G benzathine Nutrition 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 2
- 229960004919 procaine Drugs 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 150000003751 zinc Chemical class 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- 235000006491 Acacia senegal Nutrition 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 244000144725 Amygdalus communis Species 0.000 claims 1
- 235000011437 Amygdalus communis Nutrition 0.000 claims 1
- 235000005747 Carum carvi Nutrition 0.000 claims 1
- 240000000467 Carum carvi Species 0.000 claims 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims 1
- 240000008886 Ceratonia siliqua Species 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 244000303965 Cyamopsis psoralioides Species 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 229920000392 Zymosan Polymers 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 235000020224 almond Nutrition 0.000 claims 1
- 235000012216 bentonite Nutrition 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 claims 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 claims 1
- 108700023159 delta Opioid Receptors Proteins 0.000 claims 1
- 102000048124 delta Opioid Receptors Human genes 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 230000000741 diarrhetic effect Effects 0.000 claims 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920001592 potato starch Polymers 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 108020001612 μ-opioid receptors Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Eye Examination Apparatus (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Amplifiers (AREA)
- Amplitude Modulation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55334204P | 2004-03-15 | 2004-03-15 | |
| EP13173454.3A EP2653465B1 (en) | 2004-03-15 | 2005-03-14 | Opioid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02540B true ME02540B (me) | 2017-02-20 |
Family
ID=34962827
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-232A ME02540B (me) | 2004-03-15 | 2005-03-14 | Modulatori optoidnih receptora |
| MEP-2013-97A ME01601B (me) | 2004-03-15 | 2005-03-14 | Modulatori opioidnog receptora |
| MEP-2015-36A ME02221B (me) | 2004-03-15 | 2005-03-14 | Postupak za proizvodnju intermedijara jedinjenja korisnih kao modulatori opioidnih receptora |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2013-97A ME01601B (me) | 2004-03-15 | 2005-03-14 | Modulatori opioidnog receptora |
| MEP-2015-36A ME02221B (me) | 2004-03-15 | 2005-03-14 | Postupak za proizvodnju intermedijara jedinjenja korisnih kao modulatori opioidnih receptora |
Country Status (35)
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| LT2653465T (lt) | 2004-03-15 | 2016-09-12 | Janssen Pharmaceutica Nv | Opioidinio receptoriaus moduliatoriai |
| JP5420170B2 (ja) | 2004-05-14 | 2014-02-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カルボキサミド系オピオイド化合物 |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| WO2006098982A1 (en) * | 2005-03-14 | 2006-09-21 | Janssen Pharmaceutica, N.V. | Process for the preparation of opioid modulators |
| KR20080087817A (ko) | 2005-12-14 | 2008-10-01 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 ｘｉａ 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체 |
| PT1966130E (pt) | 2005-12-23 | 2014-01-30 | Zealand Pharma As | Compostos miméticos de lisina modificados |
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20080188545A1 (en) * | 2006-12-21 | 2008-08-07 | Alimardanov Asaf R | Synthesis of pyrrolidine compounds |
| EP2176234B1 (en) * | 2007-07-09 | 2016-01-27 | Forest Tosara Limited | Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid |
| DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| TWI468375B (zh) | 2008-10-27 | 2015-01-11 | Janssen Pharmaceutica Nv | 製備經保護之ｌ－丙胺酸衍生物之方法 |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| JP5198220B2 (ja) * | 2008-11-13 | 2013-05-15 | 東ソ−・エフテック株式会社 | アミノ酸誘導体の製造方法 |
| US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| EP2524912A1 (en) | 2011-05-16 | 2012-11-21 | Bionomics Limited | Amine derivatives |
| EP2709985B1 (en) | 2011-05-16 | 2017-10-04 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
| EP2970133B1 (en) * | 2013-03-14 | 2018-10-24 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| AU2014236146B2 (en) | 2013-03-14 | 2018-05-17 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| IS2977B (is) | 2015-02-23 | 2017-07-15 | Actavis Group Ptc Ehf. | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni |
| US10702498B2 (en) | 2015-07-09 | 2020-07-07 | The Regents Of The University Of California | MU opioid receptor modulators |
| WO2017015606A1 (en) * | 2015-07-23 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of eluxadoline |
| JPWO2017043626A1 (ja) * | 2015-09-11 | 2018-06-21 | 株式会社カネカ | 光学活性４−カルバモイル−２，６−ジメチルフェニルアラニン誘導体の製造法 |
| EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| CN105250232B (zh) * | 2015-09-29 | 2018-08-14 | 江苏汇智知识产权服务有限公司 | 一种伊卢多啉肠溶片及其制备方法 |
| WO2017114446A1 (zh) * | 2015-12-31 | 2017-07-06 | 苏州晶云药物科技有限公司 | 艾沙度林的新晶型及其制备方法 |
| EP3272741A1 (en) | 2016-07-21 | 2018-01-24 | Euticals S.P.A. | New stable solvate crystalline forms of eluxadoline |
| CN105777584B (zh) * | 2016-03-28 | 2018-01-02 | 成都伊诺达博医药科技有限公司 | 丙氨酸衍生物的制备方法 |
| CN105693554B (zh) * | 2016-04-06 | 2017-08-08 | 成都伊诺达博医药科技有限公司 | 丙氨酸衍生物的制备方法 |
| US20190177281A1 (en) * | 2016-05-03 | 2019-06-13 | Sromovasam THIRUMALAI RAJAN | Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof |
| WO2017208156A1 (en) * | 2016-05-30 | 2017-12-07 | Sun Pharmaceutical Industries Limited | A process for the preparation of eluxadoline |
| EP3474847B1 (en) * | 2016-06-23 | 2022-09-07 | Sun Pharmaceutical Industries Limited | Processes for the preparation of eluxadoline |
| WO2018020450A2 (en) | 2016-07-28 | 2018-02-01 | Lupin Limited | Process for the preparation of eluxadoline |
| CZ2016548A3 (cs) | 2016-09-07 | 2018-03-14 | Zentiva, K.S. | Pevné formy eluxadolinu |
| WO2018047131A1 (en) * | 2016-09-09 | 2018-03-15 | Sun Pharmaceutical Industries Limited | Amorphous eluxadoline |
| US10479769B2 (en) | 2016-09-20 | 2019-11-19 | Sun Pharmaceutical Industries Limited | Processes for the preparation of eluxadoline |
| WO2018138272A1 (en) | 2017-01-27 | 2018-08-02 | Quimica Sintetica, S. A. | Eluxadoline crystalline form and process for the preparation thereof |
| US10738013B2 (en) | 2017-01-27 | 2020-08-11 | Quimica Sintetica, S.A. | Eluxadoline crystalline forms and processes for their preparation |
| WO2018202865A1 (en) | 2017-05-05 | 2018-11-08 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
| WO2019008604A1 (en) | 2017-07-07 | 2019-01-10 | Cipla Limited | NEW FORMS OF MU-OPIOID RECEPTOR AGONIST |
| WO2019144805A1 (zh) * | 2018-01-25 | 2019-08-01 | 四川科伦博泰生物医药股份有限公司 | 取代的苯乙胺化合物及其制备方法和用途 |
| WO2019197274A1 (en) | 2018-04-09 | 2019-10-17 | Quimica Sintetica, S. A. | Process for the preparation of opioid modulators |
| WO2020039333A1 (en) | 2018-08-20 | 2020-02-27 | Allergan Holdings Unlimited Company | Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| ES2867895T3 (es) * | 2018-11-30 | 2021-10-21 | Phytobiotics Futterzusatzstoffe Gmbh | Sistema para el análisis de imágenes de excrementos de animales |
| CN111377832A (zh) * | 2018-12-27 | 2020-07-07 | 江苏联昇化学有限公司 | 一种伊卢多啉中间体制备的新方法 |
| EP3962482A4 (en) | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL |
| WO2021198780A1 (en) | 2020-03-30 | 2021-10-07 | Allergan Holdings Unlimited Company | Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
| IL300110A (en) * | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Chiral synthesis of RAF inhibitors in compressed cyclics |
| US11896728B2 (en) | 2020-09-29 | 2024-02-13 | Abl Ip Holding Llc | Techniques for directing ultraviolet energy towards a moving surface |
| US11850319B2 (en) | 2020-09-29 | 2023-12-26 | Abl Ip Holding Llc | Techniques for directing ultraviolet energy towards a moving surface |
| CN114163348A (zh) * | 2020-11-27 | 2022-03-11 | 成都泰蓉生物科技有限公司 | 一种氨酰基取代的l-苯丙氨酸的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD142804A3 (de) * | 1977-11-07 | 1980-07-16 | Wagner Guenter | Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden |
| US4879398A (en) * | 1987-12-31 | 1989-11-07 | Monsanto Company | Process for producing 2,6-disubstituted tyrosine |
| SE9402880D0 (sv) | 1994-08-30 | 1994-08-30 | Astra Ab | New peptide derivatives |
| AR003108A1 (es) * | 1995-01-27 | 1998-07-08 | Novo Nordisk As | Compuestos con propiedades de liberacion de la hormona del crecimiento, composicion farmaceutica que los contienen, el uso de los mismos para la preparación de un medicamento. |
| US5565568A (en) | 1995-04-06 | 1996-10-15 | Eli Lilly And Company | 2-acylaminopropanamides as tachykinin receptor antagonists |
| KR100414321B1 (ko) | 1995-04-13 | 2004-02-18 | 아벤티스 파마슈티칼스 인크. | 타치키닌수용체길항활성을갖는신규한치환된피페라진유도체 |
| WO1997006803A1 (en) | 1995-08-21 | 1997-02-27 | Eli Lilly And Company | 2-acylaminopropanamides as growth hormone secretagogues |
| AU7710596A (en) | 1995-11-29 | 1997-06-19 | Nihon Nohyaku Co., Ltd. | Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides |
| US5792760A (en) | 1997-04-23 | 1998-08-11 | Eli Lilly And Company | Bisindoles as tachykinin receptor antagonists |
| IT1304898B1 (it) | 1998-09-08 | 2001-04-05 | Menarini Ricerche Spa | Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche |
| PT1055665E (pt) * | 1999-05-28 | 2004-03-31 | Pfizer Prod Inc | Derivados da 3-(3-hidroxifenil)-3-amino-propionamida |
| FR2796643B1 (fr) | 1999-07-22 | 2005-04-29 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique |
| GB0021419D0 (en) | 2000-08-31 | 2000-10-18 | Oxford Glycosciences Uk Ltd | Compounds |
| US20020072017A1 (en) * | 2000-10-19 | 2002-06-13 | Hudnall Phillip Montgomery | Stabilized p-phenylenediamine-type photographic color developers in free base form |
| PL205536B1 (pl) | 2000-10-30 | 2010-04-30 | Janssen Pharmaceutica Nv | Podstawiona pochodna dihydroindolu, dihydrochinoliny lub dihydroizochinoliny jako inhibitor peptydazy tripeptydowej, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
| EA006507B1 (ru) * | 2001-10-15 | 2005-12-29 | Янссен Фармацевтика Н.В. | Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов |
| US7041681B2 (en) * | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
| LT2653465T (lt) | 2004-03-15 | 2016-09-12 | Janssen Pharmaceutica Nv | Opioidinio receptoriaus moduliatoriai |
| US7282507B2 (en) | 2004-05-03 | 2007-10-16 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (SARMS) |
| WO2006098982A1 (en) * | 2005-03-14 | 2006-09-21 | Janssen Pharmaceutica, N.V. | Process for the preparation of opioid modulators |
-
2005
- 2005-03-14 LT LTEP13173454.3T patent/LT2653465T/lt unknown
- 2005-03-14 ES ES13173454.3T patent/ES2596434T3/es not_active Expired - Lifetime
- 2005-03-14 RS RS20130371A patent/RS52933B/sr unknown
- 2005-03-14 WO PCT/US2005/008339 patent/WO2005090315A1/en not_active Ceased
- 2005-03-14 SI SI200531771T patent/SI2298744T1/sl unknown
- 2005-03-14 CA CA2560047A patent/CA2560047C/en not_active Expired - Lifetime
- 2005-03-14 ME MEP-2016-232A patent/ME02540B/me unknown
- 2005-03-14 PT PT101823490T patent/PT2298744E/pt unknown
- 2005-03-14 PL PL10182349T patent/PL2298744T3/pl unknown
- 2005-03-14 ES ES16178050T patent/ES2705077T3/es not_active Expired - Lifetime
- 2005-03-14 CN CN201210277845.6A patent/CN102786476B/zh not_active Expired - Fee Related
- 2005-03-14 RS RS20110446A patent/RS51995B/sr unknown
- 2005-03-14 TW TW094107612A patent/TWI361069B/zh not_active IP Right Cessation
- 2005-03-14 PL PL05728171T patent/PL1725537T3/pl unknown
- 2005-03-14 SI SI200531383T patent/SI1725537T1/sl unknown
- 2005-03-14 ME MEP-2013-97A patent/ME01601B/me unknown
- 2005-03-14 KR KR1020067021231A patent/KR101166342B1/ko not_active Expired - Fee Related
- 2005-03-14 CN CN200580014571XA patent/CN1950342B/zh not_active Expired - Fee Related
- 2005-03-14 DK DK13173454.3T patent/DK2653465T3/da active
- 2005-03-14 EP EP13173454.3A patent/EP2653465B1/en not_active Expired - Lifetime
- 2005-03-14 SI SI200531934T patent/SI2573068T1/sl unknown
- 2005-03-14 DK DK05728171.9T patent/DK1725537T3/da active
- 2005-03-14 EP EP05728171A patent/EP1725537B1/en not_active Expired - Lifetime
- 2005-03-14 UA UAA200609824A patent/UA86053C2/ru unknown
- 2005-03-14 JP JP2007503986A patent/JP4778954B2/ja not_active Expired - Fee Related
- 2005-03-14 ES ES10182349T patent/ES2428008T3/es not_active Expired - Lifetime
- 2005-03-14 ES ES05728171T patent/ES2367576T3/es not_active Expired - Lifetime
- 2005-03-14 EP EP10182349.0A patent/EP2298744B1/en not_active Expired - Lifetime
- 2005-03-14 HR HR20110694T patent/HRP20110694T1/hr unknown
- 2005-03-14 AU AU2005224091A patent/AU2005224091B2/en not_active Ceased
- 2005-03-14 MX MXPA06010642A patent/MXPA06010642A/es active IP Right Grant
- 2005-03-14 NZ NZ549842A patent/NZ549842A/en not_active IP Right Cessation
- 2005-03-14 HU HUE13173454A patent/HUE029852T2/en unknown
- 2005-03-14 ME MEP-2015-36A patent/ME02221B/me unknown
- 2005-03-14 DK DK10182349.0T patent/DK2298744T3/da active
- 2005-03-14 EP EP16178050.7A patent/EP3112352B1/en not_active Expired - Lifetime
- 2005-03-14 DK DK12194058.9T patent/DK2573068T3/en active
- 2005-03-14 PT PT131734543T patent/PT2653465T/pt unknown
- 2005-03-14 MY MYPI20051060A patent/MY146972A/en unknown
- 2005-03-14 BR BRPI0508820A patent/BRPI0508820B8/pt not_active IP Right Cessation
- 2005-03-14 PL PL12194058T patent/PL2573068T3/pl unknown
- 2005-03-14 EP EP12194058.9A patent/EP2573068B9/en not_active Expired - Lifetime
- 2005-03-14 RS RS20150204A patent/RS54199B1/sr unknown
- 2005-03-14 SI SI200532091A patent/SI2653465T1/sl unknown
- 2005-03-14 US US11/079,647 patent/US7741356B2/en active Active
- 2005-03-14 ES ES12194058.9T patent/ES2533176T3/es not_active Expired - Lifetime
- 2005-03-14 PT PT121940589T patent/PT2573068E/pt unknown
- 2005-03-14 PT PT05728171T patent/PT1725537E/pt unknown
- 2005-03-14 AT AT05728171T patent/ATE516274T1/de active
- 2005-03-14 DK DK16178050.7T patent/DK3112352T3/en active
- 2005-03-14 PL PL13173454T patent/PL2653465T3/pl unknown
- 2005-03-14 RS RS20160843A patent/RS55122B1/sr unknown
- 2005-03-15 AR ARP050101007A patent/AR048269A1/es active IP Right Grant
-
2006
- 2006-09-12 IL IL178040A patent/IL178040A/en active IP Right Grant
- 2006-09-15 EC EC2006006856A patent/ECSP066856A/es unknown
- 2006-09-25 CR CR8655A patent/CR8655A/es unknown
- 2006-10-13 NO NO20064660A patent/NO338203B1/no not_active IP Right Cessation
- 2006-10-13 ZA ZA2006/08587A patent/ZA200608587B/en unknown
-
2007
- 2007-10-24 US US11/877,747 patent/US7786158B2/en active Active
-
2010
- 2010-07-19 US US12/838,825 patent/US8344011B2/en not_active Expired - Lifetime
-
2011
- 2011-10-10 CY CY20111100967T patent/CY1111927T1/el unknown
-
2012
- 2012-08-14 PH PH12012501640A patent/PH12012501640A1/en unknown
- 2012-11-30 US US13/690,041 patent/US8609709B2/en not_active Expired - Lifetime
-
2013
- 2013-02-26 IL IL224908A patent/IL224908A/en active IP Right Grant
- 2013-08-22 HR HRP20130800TT patent/HRP20130800T1/hr unknown
- 2013-10-03 US US14/045,008 patent/US8772325B2/en not_active Expired - Lifetime
- 2013-11-14 IL IL229444A patent/IL229444A/en active IP Right Grant
-
2014
- 2014-04-11 AR ARP140101566A patent/AR095848A2/es unknown
- 2014-05-20 US US14/282,828 patent/US9205076B2/en not_active Expired - Lifetime
-
2015
- 2015-03-18 HR HRP20150305TT patent/HRP20150305T1/hr unknown
- 2015-10-12 US US14/880,597 patent/US9700542B2/en not_active Expired - Lifetime
-
2016
- 2016-05-30 NO NO20160916A patent/NO20160916A1/no not_active Application Discontinuation
- 2016-10-12 CY CY20161101019T patent/CY1118096T1/el unknown
- 2016-10-12 HR HRP20161331TT patent/HRP20161331T1/hr unknown
-
2017
- 2017-02-23 NO NO2017007C patent/NO2017007I1/no unknown
- 2017-03-01 LT LTPA2017005C patent/LTC1725537I2/lt unknown
- 2017-03-01 LU LU00007C patent/LUC00007I2/fr unknown
- 2017-03-02 HU HUS1700010C patent/HUS1700010I1/hu unknown
- 2017-03-08 CY CY2017008C patent/CY2017008I1/el unknown
- 2017-03-10 NL NL300865C patent/NL300865I2/nl unknown
- 2017-06-07 US US15/616,358 patent/US10213415B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02540B (me) | Modulatori optoidnih receptora | |
| DE60032749T2 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| JP2002529504A (ja) | インスリン感作物質および他の抗糖尿病薬の放出修飾のための医薬組成物 | |
| JPH10504818A (ja) | アモキシシリンおよびクラブラン酸カリウム含有の医薬処方 | |
| JP2003231634A5 (enExample) | ||
| JP2006522006A5 (enExample) | ||
| WO2011025267A2 (ko) | 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 | |
| CN105963296A (zh) | 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途 | |
| WO2011025270A2 (ko) | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제 | |
| JP2008518013A (ja) | プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 | |
| KR100681360B1 (ko) | 타액분비 촉진용 카르보스티릴 유도체 | |
| US20060121106A1 (en) | Therapeutic system comprising amoxicillin and clavulanic acid | |
| CN103054820B (zh) | 一种盐酸决奈达隆药物组合物及其制备方法 | |
| JP2010024181A (ja) | 固形製剤及びその製造方法 | |
| US8748489B2 (en) | Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent | |
| CN101317842A (zh) | 一种咪唑-5-羧酸衍生物的治疗用途 | |
| JP2012526099A5 (enExample) | ||
| US20070123568A1 (en) | Therapeutic methods using prostaglandin EP4 agonist components | |
| JP2008534563A5 (enExample) | ||
| US9029334B2 (en) | Pharmaceutical composition for prevention or treatment of bone diseases comprising spinasterol glucoside derivative | |
| JP4153124B2 (ja) | 鎮痛剤 | |
| CN101352440A (zh) | 一种美愈伪麻缓释制剂及其制备方法 | |
| US20130251793A1 (en) | Pharmaceutical composition comprising phentermine and topiramate | |
| CA2453256A1 (en) | Diphenhydramine tannate compositions and methods of use | |
| CN102370656A (zh) | 克拉霉素药物组合物及其制备方法 |